Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 76

Sort by

Sort Order Select

Journal Articles

The ABC-14 regimen (Azacitidine, Venetoclax, and Chidamide) as a bridge to allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia: A single-center experience

Xiaomei Chen, Chengwei Luo, Lisi Huang, Wei Ling, Chengxin Deng, Minming Li, Ping Wu, Peilong Lai, Xin Du, Suijing Wu, Jianyu Weng

Blood (2025) 146 (Supplement 1): 5991.

https://doi.org/10.1182/blood-2025-5991

Published: 2025

Journal Articles

ELN milestone-driven TKI switching improves deep molecular response rates in chronic myeloid leukemia

Lisi Huang, Chengxin Deng, Zesheng Lu, Minming Li, Ping Wu, Suxia Geng, Yulian Wang, Lingji Zeng, Qiong Luo, Xin Huang, Peilong Lai, Xin Du, Jianyu Weng

Blood (2025) 146 (Supplement 1): 5563.

https://doi.org/10.1182/blood-2025-5563

Published: 2025

Journal Articles

Interim results from a multicenter trial assessing the clinical relevance of copy number aberrations detected by a shallow whole-genome sequencing analysis (LeukoPrint) in multiple myeloma.

Li Gao, Liping Su, Fengyan Jin, Zhongxing Jiang, Jianyu Weng, Baijun Fang, Zhenyu Li, Lin Qiu, Chenyu Ding, Lijuan Zhang, Manqian Li, Yinyin Chang, Wei Gong, Xi Zhang, Shichun Tu

Blood (2025) 146 (Supplement 1): 3982.

https://doi.org/10.1182/blood-2025-3982

Published: 2025

Journal Articles

Interim results of a multi-center clinical trial evaluating copy number aberrations via shallow whole-genome sequencing (LeukoPrint) in Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 5245.

https://doi.org/10.1182/blood-2025-5245

Published: 2025

Journal Articles

Results of POLARIS-1, a global Phase 3 study (Part A): Olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)

Blood (2025) 146 (Supplement 1): 1574.

https://doi.org/10.1182/blood-2025-1574

Published: 2025

Journal Articles

Efficacy of tgrx-678, a potent BCR::ABL1 allosteric inhibitor, in CML-CP and CML-AP patients harboring T315I mutation: Results from a phase 1 study

Qian Jiang, Weiming Li, Yanli Zhang, Qiang WANG, Suning Chen, Bingcheng LIU, Jie Jin, Zhenfang Liu, Zhuogang Liu, Jianyu Weng, Xin Du, Xielan Zhao, Li Meng, Shujie Yan, xiaomeng Dong, Yihan Wang, Jingrong Cao

Blood (2025) 146 (Supplement 1): 902.

https://doi.org/10.1182/blood-2025-902

Published: 2025

Journal Articles

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Blood (2024) 144 (Supplement 1): 4748.

https://doi.org/10.1182/blood-2024-202893

Published: 2024

Journal Articles

Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis

Blood (2024) 144 (Supplement 1): 4529.

https://doi.org/10.1182/blood-2024-203533

Published: 2024

Journal Articles

Predictive Models for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Fang Cheng, Yu Wang, Xin Du, Yu Zhu, Jianyu Weng, Na Xu, Yunfan Yang, Jian Huang, Zhenfang Liu, Hongbo Ren, Huifang Zhao, Yajuan Ke, Weiyan Wu, Huanling Zhu, Qian Jiang, Yanli Zhang, Weiming Li

Blood (2024) 144 (Supplement 1): 4540.

https://doi.org/10.1182/blood-2024-202876

Published: 2024

Journal Articles

MRD-Driven Prophylactic or Pre-Emptive Intervention with Chidamide-Based Treatment for High-Risk AML Relapse Post-Transplantation: A Real-World Experience from a Chinese Single Center

Ping Wu, Wei Ling, Chengwei Luo Luo, Lisi Huang, Ruohao Xu, Xiaoling Liang, Jiaqi Tan, Jinghua Wang, Peilong Lai, Suijing Wu, Birong Li, Haijie Huang, Suxia Geng, Xin Du, Jianyu Weng

Blood (2024) 144 (Supplement 1): 1575.

https://doi.org/10.1182/blood-2024-210697

Published: 2024

Journal Articles

Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)

Huafeng Wang, Xudong Wei, Yang Liang, Jianyu Weng, Wenjuan He, Chunkang Chang, Suning Chen, Hongbing Ma, Zi Chen, Lichuang Men, Lihui Liu, Xiaohong Tian, Zhang Zhang, Danhua Cong, Dajun Yang, Yifan Zhai, Jie Jin

Blood (2024) 144 (Supplement 1): 3202.

https://doi.org/10.1182/blood-2024-205371

Published: 2024

Journal Articles

Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001

Qian Jiang, Li Weiming, Yanli Zhang, Qiang Wang, Suning Chen, Bingcheng Liu, Zhuogang Liu, Jie Jin, Zhenfang Liu, Jianyu Weng, Xin Du, Xielan Zhao, Li Meng, Lie Lin, Wanlin Ye, Shujie Yan, Yihan Wang, Jingrong Cao

Blood (2024) 144 (Supplement 1): 477.

https://doi.org/10.1182/blood-2024-205300

Published: 2024

Journal Articles

Azacitidine, Venetoclax Combined with Chidamide (ABC-14 Regimen) As an Induction Therapy for Newly Diagnosed AML: A Real-World Retrospective Analysis By the ABC-14 Collaboration Group

Blood (2024) 144 (Supplement 1): 6014.

https://doi.org/10.1182/blood-2024-210211

Published: 2024

Journal Articles

Single-Cell Analysis Reveals Altered Tumor Microenvironments of Relapse/ Refractory and Remission-Associated Acute Myeloid Leukemia Treated By ABC-14 Regimen

Xin Huang, Minming Li, Ping Wu, Chengxin Deng, Zesheng Lu, Yulian Wang, Suxia Geng, Chengwei Luo Luo, Peilong Lai, Xin Du, Jianyu Weng

Blood (2024) 144 (Supplement 1): 5802.

https://doi.org/10.1182/blood-2024-204516

Published: 2024

Journal Articles

Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China

Blood (2024) 144 (Supplement 1): 1767.

https://doi.org/10.1182/blood-2024-206453

Published: 2024

Journal Articles

Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study

Qian Jiang, Yanli Zhang, Qiang Wang, Jianyu Weng, Zhenfang Liu, Suning Chen, Li Weiming, Bingcheng Liu, Zhuogang Liu, Yihan Wang, Jingrong Cao

Blood (2023) 142 (Supplement 1): 867.

https://doi.org/10.1182/blood-2023-185977

Published: 2023

Journal Articles

Chidamide-Based Pre-Emptive Treatment for High-Risk AML Patients after Hematopoietic Stem Cell Transplantation: A Real-World Experience from Chinese Single-Center

Ping Wu, Wei Ling, Chengwei Luo, Xiaomei Chen, Lisi Huang, Jinghua Wang, Peilong Lai, Suijing Wu, Xin Du, Jianyu Weng

Blood (2023) 142 (Supplement 1): 2890.

https://doi.org/10.1182/blood-2023-187924

Published: 2023

Journal Articles

Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naïve (TN) Patients (Pts) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms

Blood (2023) 142 (Supplement 1): 2925.

https://doi.org/10.1182/blood-2023-188489

Published: 2023

Journal Articles

ABC Regimen (Azacitidine, Venetoclax and Chidamide) Is Comparable to the “3+7” Regimen in Newly Diagnosed AML: A Real-World Experience from South China

Blood (2023) 142 (Supplement 1): 1522.

https://doi.org/10.1182/blood-2023-188196

Published: 2023

Journal Articles

Treatment-Free Remission Era: BCR-ABL1 mRNA Transcript Level <5% at 3 Months Predicts 24-Month Deep Molecular Response and Better Survival

Lisi Huang, Suxia Geng, Yulian Wang, Zesheng Lu, Chengxin Deng, Xin Huang, Minming Li, Lingji Zeng, Qiong Luo, Peilong Lai, Xin Du, Jianyu Weng

Blood (2023) 142 (Supplement 1): 4545.

https://doi.org/10.1182/blood-2023-185222

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

The ABC-14 regimen (Azacitidine, Venetoclax, and Chidamide) as a bridge to allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia: A single-center experience

ELN milestone-driven TKI switching improves deep molecular response rates in chronic myeloid leukemia

Interim results from a multicenter trial assessing the clinical relevance of copy number aberrations detected by a shallow whole-genome sequencing analysis (LeukoPrint) in multiple myeloma.

Interim results of a multi-center clinical trial evaluating copy number aberrations via shallow whole-genome sequencing (LeukoPrint) in Acute Myeloid Leukemia

Results of POLARIS-1, a global Phase 3 study (Part A): Olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)

Efficacy of tgrx-678, a potent BCR::ABL1 allosteric inhibitor, in CML-CP and CML-AP patients harboring T315I mutation: Results from a phase 1 study

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis

Predictive Models for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

MRD-Driven Prophylactic or Pre-Emptive Intervention with Chidamide-Based Treatment for High-Risk AML Relapse Post-Transplantation: A Real-World Experience from a Chinese Single Center

Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)

Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001

Azacitidine, Venetoclax Combined with Chidamide (ABC-14 Regimen) As an Induction Therapy for Newly Diagnosed AML: A Real-World Retrospective Analysis By the ABC-14 Collaboration Group

Single-Cell Analysis Reveals Altered Tumor Microenvironments of Relapse/ Refractory and Remission-Associated Acute Myeloid Leukemia Treated By ABC-14 Regimen

Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China

Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study

Chidamide-Based Pre-Emptive Treatment for High-Risk AML Patients after Hematopoietic Stem Cell Transplantation: A Real-World Experience from Chinese Single-Center

Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naïve (TN) Patients (Pts) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms

ABC Regimen (Azacitidine, Venetoclax and Chidamide) Is Comparable to the “3+7” Regimen in Newly Diagnosed AML: A Real-World Experience from South China

Treatment-Free Remission Era: BCR-ABL1 mRNA Transcript Level <5% at 3 Months Predicts 24-Month Deep Molecular Response and Better Survival

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only